 |
市場調査レポート
商品コード
967751
薬価・償還 (P&R) におけるイノベーション：2020年Innovations in Drug Pricing and Reimbursement 2020 |
||||||
| 薬価・償還 (P&R) におけるイノベーション：2020年 |
|
出版日: 2020年10月14日
発行: FirstWord
ページ情報: 英文
納期: 即日から翌営業日
|
COVID-19は、薬価・償還 (P&R) プロセスに新たな圧力を導入し、デジタルテクノロジーの使用を加速させました。しかし、このことが、新たな問題を提起しました。
当レポートでは、P&Rを成功させるための運営環境を形成しているアプローチ・技術・取引構造について、COVID-19の観点から検証し、体系的な情報を提供しています。
What are the trends and technologies that could deliver a better understanding of payers' needs and build improved evidence of value? COVID-19 has introduced new pressures into the pricing and reimbursement (P&R) process and has accelerated the use of digital technology. But this has raised new questions. Are virtual payer and advisory board meetings really working? Will innovative AI driven tools really identify evidence gaps and usher in streamlined processes? When would novel approaches such as Novartis' "Day One Access" and Vertex's Portfolio models be appropriate?
To identify the latest innovations in P&R, we interviewed US and European industry experts. In ‘Innovations in Pricing and Reimbursement’ they examine, in the light of COVID-19, the approaches, technologies and deal structures that are shaping the operating landscape for successful P&R.
"It's more difficult to read between the lines on a computer screen. The more sensitive the issues you want to discuss then you want to have a face-to-face meeting. The more you shift the discussions from horizon scanning and into evidence and then into the negotiations, when it's the numbers, the pricing, is where it's more important to have face-to-face interactions. You need to make your offers and to probe to get counter-proposals."Senior market access director , Germany.
"Day one access programmes may set a precedent, but that can be good or bad. This might be a way to manoeuvre for a better final deal by getting agreement in principle to a temporary deal. The company might be willing to loss lead a little because it's only temporary. But the company might fall into the pitfall of then when it comes to negotiating a final deal, having that held up as a benchmark. So there are commercial pros and cons." Market access director , UK.
"The Academy of Managed Care Pharmacy (AMCP) include manufacturers, payers and others. The AMCP dossier, the paper version, is usually, say 150 pages, and comes out when a new product is launched. It includes everything from the clinical evidence base, it includes the economic value, budget impact. All of that is in the dossier. So this new digital platform will have the AMCP dossier in it. It offers the ability to learn about the product, but also to cross reference to learn about other products in the same therapeutic category. The interesting thing with the AMCP platform is that when I am launching a product I will be able to put in my analogues so that payer can look at my product through that lens, not just the sole category for my product. We can buy a learning place and we can feed in information." VP, market access , HEOR and public policy, US.
A detailed report revealing expert insights on the innovative approaches and digital technologies that are influencing successful P&R practice.
Innovations in Pricing and Reimbursement is delivered as:
Experts contributing to this report have been screened to ensure they:
FirstWord's ExpertViews reports reveal the real world insights of knowledgeable experts to analyze in detail key commercial and market trends that pharma management need to understand if they are to effectively respond to critical developments. These highly-focussed reports:
比較リスト
